No photo of Maria K Hordinsky
Contact Expert

View Scopus Profile

Maria K Hordinsky

1982 …2024

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY ANDSAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSIONPERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 ANDPF-067008

Hordinsky, M. K.

PFIZER, INC.

6/20/19 → 6/30/24

Project: Research project

    • A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY ANDEFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

    Hordinsky, M. K.

    PFIZER, INC.

    6/17/19 → 6/30/24

    Project: Research project

    • Open-Label Study of ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), AlopeciaUniversalis (AU) and Alopecia Totalis (AT)

    Hordinsky, M. K.

    ACLARIS THERAPEUTICS, INC

    1/4/19 → 1/31/24

    Project: Research project

    A Phase 2B/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-06651600 in Adult and Adolescent Alopecia Areata (AA) Subjects with 50% or Greater Scalp Hair Loss

    Hordinsky, M. K.

    PFIZER, INC.

    10/9/18 → 10/30/23

    Project: Research project

    • A Multicenter, Randomized, Double-Blind, PlaceboControlled, Operationally Seamless, Adaptive Phase 2/3Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very SevereAlopecia Areata

    Hordinsky, M. K.

    Eli Lilly and Company

    8/6/18 → 8/30/23

    Project: Research project

    • Research Output

    Evidence for neurogenic inflammation in lichen planopilaris and frontal fibrosing alopecia pathogenic mechanism

    Doche, I., Wilcox, G. L., Ericson, M., Valente, N. S., Romiti, R., McAdams, B. D. & Hordinsky, M. K., Mar 1 2020, In : Experimental Dermatology. 29, 3, p. 282-285 4 p.

    Research output: Contribution to journal › Article

    • 2 Scopus citations

    Familial implications of autoimmune disease: Recurrence risks of alopecia areata and associated conditions in first-degree relatives

    Agre, K., McCarthy Veach, P., Bemmels, H., Wiens, K., LeRoy, B. S. & Hordinsky, M., Feb 1 2020, In : Journal of Genetic Counseling. 29, 1, p. 35-43 9 p.

    Research output: Contribution to journal › Article

    • Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study

    Olsen, E. A., Kornacki, D., Sun, K. & Hordinsky, M. K., Feb 2020, In : Journal of the American Academy of Dermatology. 82, 2, p. 412-419 8 p.

    Research output: Contribution to journal › Article

    • “Normal-appearing” scalp areas are also affected in lichen planopilaris and frontal fibrosing alopecia: An observational histopathologic study of 40 patients

    Doche, I., Romiti, R., Hordinsky, M. K. & Valente, N. S., Mar 1 2020, In : Experimental Dermatology. 29, 3, p. 278-281 4 p.

    Research output: Contribution to journal › Article

    • 4 Scopus citations

    Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand–foot syndrome: a newly recognized toxicity

    Pease, D. F., Peterson, B. A., Gilles, S., Hordinsky, M. K., Bohjanen, K. A. & Skubitz, K. M., Jul 1 2019, In : Cancer chemotherapy and pharmacology. 84, 1, p. 217-221 5 p.

    Research output: Contribution to journal › Article